A5054765556- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Neuroblastoma Research and Treatments
- Testicular diseases and treatments
- Bladder and Urothelial Cancer Treatments
- Epigenetics and DNA Methylation
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Renal and related cancers
- Histone Deacetylase Inhibitors Research
- Economic and Financial Impacts of Cancer
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Phagocytosis and Immune Regulation
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Brain Metastases and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Colorectal Cancer Treatments and Studies
University of Lausanne
2025
CUF Porto Hospital
2021-2025
Hospital of St. Francis Xavier
2025
Instituto Português de Oncologia Francisco Gentil
2017-2024
Centro Hospitalar de Lisboa Ocidental
2020-2022
Centro Hospitalar de Lisboa Central
2022
Champalimaud Foundation
2022
Hospital Beatriz Ângelo
2022
Centro De Medicina Veterinária Anjos De Assis
2022
Hospital de São Bernardo
2022
Introduction In clinical practice, there is a binary distinction between human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative (HER2-) breast cancer (BC). However, within HER2- disease, significant heterogeneity. Particularly, tumors that express some level of HER2 by immunohistochemistry (IHC) score 1+ or 2+/in situ hybridization (ISH) non-amplified are currently defined as HER2-low. This subgroup has shown distinct biological features compared to HER2-zero (HER2-0) BC...
Background: Breast cancer (BrC) is the most frequent neoplasm in women. New biomarkers, including aberrant DNA methylation, may improve BrC management. Herein, we evaluated detection and prognostic performance of seven genes’ promoter methylation (APC, BRCA1, CCND2, FOXA1, PSAT1, RASSF1A SCGB3A1). Methods: Methylation levels were assessed primary tissues by quantitative methylation-specific polymerase chain reaction (QMSP) circulating cell-free (ccfDNA) multiplex QMSP from two independent...
TPS579 Background: The standard management of MIBC involves neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy and pelvic lymph node dissection. Approximately 40% patients with are cisplatin ineligible, the care (SoC) for these is to proceed directly as there no effective or approved therapies in this setting. Only nivolumab has been adjuvant treatment who at high risk recurrence after resection. Given this, remains an unmet need. D (anti–PD-L1 antibody) +T (anti–CTLA-4...
BackgroundLeptomeningeal metastases (LM) in patients with breast cancer (BC) are associated a dismal prognosis. We explored clinical characteristics and prognostic factors BC LM the German Brain Metastases Breast Cancer Registry.MethodsAll histologically confirmed diagnosis of (defined as presence tumor cells cerebrospinal fluid, or typical symptoms combination magnetic resonance imaging findings) were included.ResultsA total 3857 included analysis (n=859 (22.3%) LM). Among median...
Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used practice. We conducted a cross-sectional survey (November 2023-April 2024) among healthcare professionals (HCPs) the European Organisation for Research and Treatment of Cancer (EORTC). Descriptive statistics chi-square tests assessed PROM use patterns, regional differences, barriers. Binary regression models compared barriers...
Perceived risk and fear of recurrence in patients with breast cancer (BC) is a matter concern may affect their health behaviours ability to participate decision making during treatment. This survey aimed examine perceptions concerns HER2+ BC. A multi-country, non-interventional, direct-to-patient online was conducted between July 22, 2022 March 1, 2023 six European countries using multi-modal recruitment approach. Out 622 included patients, 96.8 % desired involvement treatment decisions,...
Breast cancer (BrC) is the most frequent malignancy and leading cause of death among women worldwide. Approximately 70% BrC are classified as luminal-like subtype, expressing estrogen receptor. One common effective adjuvant therapies for this subtype endocrine therapy. However, its effectiveness limited, with relapse occurring in up to 40% patients. Because microRNAs have been associated several mechanisms underlying resistance sensitivity, they may serve predictive and/or prognostic...
Locally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses chemotherapy. The increasingly use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) different settings has led clinical trials focusing on this strategy as a primary treatment, promising results. impact microbiota cancer, and vice-versa, is an emerging topic...
Background Inflammation is a crucial component in carcinogenesis. The neutrophil-to-eosinophil ratio (NER) has been studied as biomarker of prognosis and predictive response metastatic renal cell carcinoma (mRCC). In the present study, we evaluated relevance baseline NER on progression-free survival (PFS) overall (OS) outcomes real-world patients with mRCC treated nivolumab second or subsequent lines. We also assessed association objective response, well toxicity histology. Methods this...
Cancer care providers have faced many challenges in delivering safe for patients during the COVID-19 pandemic. This cross-sectional survey-based study investigated impact of pandemic on clinical practices Portuguese medical oncologists caring with breast cancer.An anonymous online survey comprising 42 questions gathered information regarding testing, treatment (neo)adjuvant and metastatic settings, other aspects cancer management. Practices before were compared, potential differences...
Breast cancer (BC) is a major health concern and better understanding of its biology might improve treatment decisions patient outcomes. Histone3 Lysine27 tri-methylation (H3K27me3) post-translational histone modification frequently associated with altered gene expression. In BC patients, lower H3K27me3 expression has been worse prognosis. We assessed immunoexpression digital imaging software assistance, in cohort luminal-like patients long-term follow-up time evaluated association...
Abstract Background Seminoma accounts for 30–50% of testicular germ cell tumors (TGCT)—the most common solid malignancy in men aged 15–35 years. The American Joint Committee on Cancer (AJCC) 8th edition (2018) created the subclassifications pT1a (tumor size < 3 cm) and pT1b (≥ cm), despite not being universally recognized. Rete testis invasion (RTI) tumor > 4 cm are considered features associated with a higher recurrence risk, but formally used staging. authors propose further...
Abstract Background Breast cancer remains the most prevalent in women globally, with Human Epidermal Growth Factor Receptor 2 positivity (HER2+) observed 15-30% of initial breast cases. Adjuvant treatment for HER2+ early has notably reduced mortality and recurrence rates. However, heterogeneity disease conveying risk information by healthcare providers (HCPs) leaves many uncertain about their individual potential (tx) options. Evidence shows that fear recurrence, uncertainty prognosis,...